Total second quarter revenue of $31.5 million increased 62% year-over-year on continued recovery and expansion from impact of COVID-19 pandemic
Second quarter clinical laboratory revenue of $24.0 million increased 92% on significant volume and pricing growth due to improved product mix
Consolidated quarterly gross margin of 50% improved 2000 basis points year-over-year
Achieved adjusted EBITDA at $4.3 million for the quarter with increases in sequential and YOY profitability
EPS of $0.05 for the quarter vs. EPS loss of ($0.16) in Q2 2020
Dr. Elazar Rabbani, Founder and CEO, to step down as CEO and transition to a scientific role with the Company once a qualified successor is identified and hired by the Board
Executive search firm Korn Ferry engaged to identify CEO candidates
Gary M. Huff, former LabCorp Diagnostics CEO, named Strategic Consultant to Board
Enzo retains Cain Brothers to help identify, evaluate, and execute strategic initiatives
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.